TrialLancet (London, England)2021

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

Anthony Marson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.